Consultants and pharmaceutical companies alike control the market intelligence channels to better understand their target patient population. Big Data offers a lot of opportunities to optimize commercial strategies from helping to identify opportunities for new therapies to assessing the success of current products. Surveyed companies are using Big Data initiatives to better target products or to assess the performance of products already on the market. Pharmacy companies are more likely to focus Big Data initiatives on current products, mainly on the success of drugs on the market. Many surveyed consultant companies use Big Data to assist in developing new therapies compared to the pharmaceutical companies. As data become more useful and the benefits more obvious, the prevalence of Big Data-driven market intelligence initiatives will continue to increase. A decision on regulations guiding social media marketing in particular also help companies decide which market intelligence strategies to attack. From the earliest to latest stages of drug marketing, companies are working quickly to discover the opportunities posed by Big Data. Read more at: